SE9103752D0 - New compounds - Google Patents

New compounds

Info

Publication number
SE9103752D0
SE9103752D0 SE9103752A SE9103752A SE9103752D0 SE 9103752 D0 SE9103752 D0 SE 9103752D0 SE 9103752 A SE9103752 A SE 9103752A SE 9103752 A SE9103752 A SE 9103752A SE 9103752 D0 SE9103752 D0 SE 9103752D0
Authority
SE
Sweden
Prior art keywords
new compounds
phenylmethyl
indol
piperazinyl
dihydro
Prior art date
Application number
SE9103752A
Other languages
English (en)
Inventor
B R Boar
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9103752A priority Critical patent/SE9103752D0/sv
Publication of SE9103752D0 publication Critical patent/SE9103752D0/sv
Priority to APAP/P/1992/000464A priority patent/AP389A/en
Priority to ZA929700A priority patent/ZA929700B/xx
Priority to IL104107A priority patent/IL104107A0/xx
Priority to JP5510848A priority patent/JPH07502272A/ja
Priority to CA002124826A priority patent/CA2124826A1/en
Priority to PL92304124A priority patent/PL170736B1/pl
Priority to HU9401844A priority patent/HUT69704A/hu
Priority to PCT/SE1992/000873 priority patent/WO1993012085A1/en
Priority to SK734-94A priority patent/SK278321B6/sk
Priority to CZ941466A priority patent/CZ146694A3/cs
Priority to EP93900490A priority patent/EP0624156A1/en
Priority to AU31759/93A priority patent/AU675055B2/en
Priority to MX9207382A priority patent/MX9207382A/es
Priority to IS3958A priority patent/IS3958A/is
Priority to TNTNSN92114A priority patent/TNSN92114A1/fr
Priority to CN92115358A priority patent/CN1034939C/zh
Priority to SI19929200405A priority patent/SI9200405A/sl
Priority to BG98815A priority patent/BG98815A/bg
Priority to NO942316A priority patent/NO942316L/no
Priority to FI942913A priority patent/FI942913A/sv
Priority to EE9400428A priority patent/EE9400428A/xx
Priority to US08/467,695 priority patent/US5585378A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
SE9103752A 1991-12-18 1991-12-18 New compounds SE9103752D0 (sv)

Priority Applications (23)

Application Number Priority Date Filing Date Title
SE9103752A SE9103752D0 (sv) 1991-12-18 1991-12-18 New compounds
APAP/P/1992/000464A AP389A (en) 1991-12-18 1992-12-14 Indol-2-one compounds and their preparation.
ZA929700A ZA929700B (en) 1991-12-18 1992-12-14 Piperidinyl and pieraziny alkyl indolones.
IL104107A IL104107A0 (en) 1991-12-18 1992-12-15 New compounds and compositions
AU31759/93A AU675055B2 (en) 1991-12-18 1992-12-16 Isatin derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
CZ941466A CZ146694A3 (en) 1991-12-18 1992-12-16 Isatin derivatives, process of their preparation and pharmaceutical composition containing thereof
CA002124826A CA2124826A1 (en) 1991-12-18 1992-12-16 Isatin derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
PL92304124A PL170736B1 (pl) 1991-12-18 1992-12-16 Sposób wytwarzania nowych pochodnych izatyny PL
HU9401844A HUT69704A (en) 1991-12-18 1992-12-16 Isatin derivatives, process for the preparation thereof and pharmaceutical compositions comprising the same
PCT/SE1992/000873 WO1993012085A1 (en) 1991-12-18 1992-12-16 Isatin derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
SK734-94A SK278321B6 (en) 1991-12-18 1992-12-16 Isatin derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
JP5510848A JPH07502272A (ja) 1991-12-18 1992-12-16 新規な化合物
EP93900490A EP0624156A1 (en) 1991-12-18 1992-12-16 Isatin derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
IS3958A IS3958A (is) 1991-12-18 1992-12-17 Ný efnasambönd sem hafa virkni í meðferð, milliefni til að nota við tilbúning þeirra og aðferð við framleiðslu þeirra
MX9207382A MX9207382A (es) 1991-12-18 1992-12-17 Nuevos compuestos que tienen actividad terapeutica intermediarios para su preparacion, proceso para obtencion de tales compuestos y formulacion farmaceutica que los contiene.
TNTNSN92114A TNSN92114A1 (fr) 1991-12-18 1992-12-18 Nouveaux composes
CN92115358A CN1034939C (zh) 1991-12-18 1992-12-18 有胆碱能活性的吲哚酮和吲哚二酮的衍生物的制备方法
SI19929200405A SI9200405A (en) 1991-12-18 1992-12-18 New indole and indoldion derivatives, process and intermediates for the preparation thereof and pahrmaceutical composition comprising the same
BG98815A BG98815A (bg) 1991-12-18 1994-05-31 Производни на изатин,метод за получаването им и фармацевтични състави,които ги съдържат
NO942316A NO942316L (no) 1991-12-18 1994-06-17 Isatinderivater, fremgangsmåter for deres fremstilling og farmasöytisk preparat omfattende slike derivater
FI942913A FI942913A (sv) 1991-12-18 1994-06-17 Isatinderivat, förfarande för deras framställning och farmaceutiska kompositioner innehållande dem
EE9400428A EE9400428A (et) 1991-12-18 1994-11-23 Isatiini derivaadid, nende valmistamise protsess, neid sisaldavad ravimvormid ja nende kasutamine
US08/467,695 US5585378A (en) 1991-12-18 1995-06-06 Composition containing an oxoindole compound

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9103752A SE9103752D0 (sv) 1991-12-18 1991-12-18 New compounds

Publications (1)

Publication Number Publication Date
SE9103752D0 true SE9103752D0 (sv) 1991-12-18

Family

ID=20384648

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9103752A SE9103752D0 (sv) 1991-12-18 1991-12-18 New compounds

Country Status (23)

Country Link
US (1) US5585378A (sv)
EP (1) EP0624156A1 (sv)
JP (1) JPH07502272A (sv)
CN (1) CN1034939C (sv)
AP (1) AP389A (sv)
AU (1) AU675055B2 (sv)
BG (1) BG98815A (sv)
CA (1) CA2124826A1 (sv)
CZ (1) CZ146694A3 (sv)
EE (1) EE9400428A (sv)
FI (1) FI942913A (sv)
HU (1) HUT69704A (sv)
IL (1) IL104107A0 (sv)
IS (1) IS3958A (sv)
MX (1) MX9207382A (sv)
NO (1) NO942316L (sv)
PL (1) PL170736B1 (sv)
SE (1) SE9103752D0 (sv)
SI (1) SI9200405A (sv)
SK (1) SK278321B6 (sv)
TN (1) TNSN92114A1 (sv)
WO (1) WO1993012085A1 (sv)
ZA (1) ZA929700B (sv)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620973A (en) * 1993-11-30 1997-04-15 Takeda Chemical Industries, Ltd. Tetracyclic condensed heterocyclic compounds and their use
SE9504267D0 (sv) * 1995-11-29 1995-11-29 Astra Ab New therapeutic use
GB2308362A (en) 1995-12-19 1997-06-25 Lilly Industries Ltd Pharmaceutical indole derivatives
WO1998007431A1 (en) * 1996-08-22 1998-02-26 New York University Cholinesterase inhibitors for treatment of parkinson's disease
WO1998008816A1 (fr) * 1996-08-26 1998-03-05 Meiji Seika Kaisha, Ltd. Derives d'indoxyle et psychotropes
WO1999044608A1 (en) 1998-03-06 1999-09-10 Astrazeneca Ab New use
GB9810886D0 (en) * 1998-05-13 1998-07-22 Lilly Industries Ltd Pharmaceutical compounds
GB9820489D0 (en) * 1998-09-22 1998-11-11 Steiger Malcolm J Compounds for improved treatment of parkinson's disease
EP1891954A3 (en) 1998-09-30 2009-01-14 Takeda Pharmaceutical Company Limited Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US6380178B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Cyclic regimens using cyclocarbamate and cyclic amide derivatives
US6306851B1 (en) 1999-05-04 2001-10-23 American Home Products Corporation Cyclocarbamate and cyclic amide derivatives
US6423699B1 (en) 1999-05-04 2002-07-23 American Home Products Corporation Combination therapies using benzimidazolones
US6339098B1 (en) 1999-05-04 2002-01-15 American Home Products Corporation 2,1-benzisothiazoline 2,2-dioxides
US6399593B1 (en) 1999-05-04 2002-06-04 Wyeth Cyclic regimens using cyclic urea and cyclic amide derivatives
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6358947B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6319912B1 (en) 1999-05-04 2001-11-20 American Home Products Corporation Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
US6417214B1 (en) 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
US6444668B1 (en) 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US6329416B1 (en) 1999-05-04 2001-12-11 American Home Products Corporation Combination regimens using 3,3-substituted indoline derivatives
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US20030153598A1 (en) * 2000-07-25 2003-08-14 Raymond Pratt Methods for treating Parkinson's disease with cholinesterase inhibitors
EP2133078A1 (en) * 2000-03-03 2009-12-16 Eisai R&D Management Co., Ltd. Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
CN1317276C (zh) * 2000-09-29 2007-05-23 中国科学院上海药物研究所 一类吲哚基哌啶类化合物及其制备方法和用途
WO2002070478A1 (en) 2001-03-06 2002-09-12 Astrazeneca Ab Indolone derivatives having vascular-damaging activity
US6770638B2 (en) 2001-04-20 2004-08-03 Spectrum Pharmaceuticals, Inc. Tetrahydroindolone and purine derivatives linked to arylpiperazines
DE60223031T2 (de) * 2001-07-30 2008-07-24 Spectrum Pharmaceuticals, Inc., Irvine Arylpiperazin gebundene tetrahydroindolonderivate
EP1764134B1 (en) * 2001-07-30 2009-01-28 Spectrum Pharmaceuticals, Inc. Purine derivatives linked to arylpiperazines
WO2005030148A2 (en) * 2003-09-25 2005-04-07 Cenomed, Inc. Tetrahydroindolone derivatives for treatment of neurological conditions
US20050107439A1 (en) * 2003-11-10 2005-05-19 Helton David R. Composition and method for treating emesis
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
MY150958A (en) * 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
US10052497B2 (en) 2005-07-22 2018-08-21 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
US9274099B2 (en) 2005-07-22 2016-03-01 The Board Of Trustees Of The Leland Stanford Junior University Screening test drugs to identify their effects on cell membrane voltage-gated ion channel
US9238150B2 (en) 2005-07-22 2016-01-19 The Board Of Trustees Of The Leland Stanford Junior University Optical tissue interface method and apparatus for stimulating cells
WO2007024391A2 (en) 2005-07-22 2007-03-01 The Board Of Trustees Of The Leland Stanford Junior University Light-activated cation channel and uses thereof
US8926959B2 (en) 2005-07-22 2015-01-06 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
US8398692B2 (en) 2007-01-10 2013-03-19 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
WO2008101128A1 (en) 2007-02-14 2008-08-21 The Board Of Trustees Of The Leland Stanford Junior University System, method and applications involving identification of biological circuits such as neurological characteristics
WO2008106694A2 (en) 2007-03-01 2008-09-04 The Board Of Trustees Of The Leland Stanford Junior University Systems, methods and compositions for optical stimulation of target cells
US10434327B2 (en) 2007-10-31 2019-10-08 The Board Of Trustees Of The Leland Stanford Junior University Implantable optical stimulators
US10035027B2 (en) 2007-10-31 2018-07-31 The Board Of Trustees Of The Leland Stanford Junior University Device and method for ultrasonic neuromodulation via stereotactic frame based technique
EP2219648A4 (en) * 2007-11-09 2010-11-03 Cenomed Biosciences Llc TREATMENT OF POSTRAUMATIC STRESS WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS
US20090264443A1 (en) * 2008-04-18 2009-10-22 David Helton Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
ES2608498T3 (es) 2008-04-23 2017-04-11 The Board Of Trustees Of The Leland Stanford Junior University Sistemas, métodos y composiciones para la estimulación óptica de células diana
CA2726128C (en) 2008-05-29 2016-10-18 The Board Of Trustees Of The Leland Stanford Junior University Cell line, system and method for optical control of secondary messengers
BRPI0915583A2 (pt) 2008-06-17 2016-01-26 Univ Leland Stanford Junior aparelho e métodos para controle do desenvolvimento celular
WO2010006049A1 (en) 2008-07-08 2010-01-14 The Board Of Trustees Of The Leland Stanford Junior University Materials and approaches for optical stimulation of the peripheral nervous system
NZ602416A (en) 2008-11-14 2014-08-29 Univ Leland Stanford Junior Optically-based stimulation of target cells and modifications thereto
WO2010090680A1 (en) * 2008-12-15 2010-08-12 Wyeth Llc Substituted oxindole cb2 agonists
US9079940B2 (en) 2010-03-17 2015-07-14 The Board Of Trustees Of The Leland Stanford Junior University Light-sensitive ion-passing molecules
US8598156B2 (en) 2010-03-25 2013-12-03 Glaxosmithkline Llc Chemical compounds
CN101863823B (zh) * 2010-06-03 2012-02-08 山东大学 吲哚二酮类化合物及其扩环衍生物、制备方法及应用
US8932562B2 (en) 2010-11-05 2015-01-13 The Board Of Trustees Of The Leland Stanford Junior University Optically controlled CNS dysfunction
CN103298480B (zh) 2010-11-05 2016-10-12 斯坦福大学托管董事会 记忆功能的控制和表征
WO2012061679A2 (en) 2010-11-05 2012-05-10 The Board Of Trustees Of The Leland Stanford Junior University Light-activated chimeric opsins and methods of using the same
CN105941328B (zh) 2010-11-05 2019-04-09 斯坦福大学托管董事会 一种鉴定抑制前额叶皮质中的兴奋性或抑制性神经元的去极化的化合物的***
CN103476456B (zh) * 2010-11-05 2017-10-03 斯坦福大学托管董事会 奖赏相关行为的光遗传学控制
JP6145043B2 (ja) 2010-11-05 2017-06-07 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 光遺伝的方法で使用するための光の上方変換
US8696722B2 (en) 2010-11-22 2014-04-15 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic magnetic resonance imaging
EP3524676A1 (en) 2011-12-16 2019-08-14 The Board of Trustees of The Leland Stanford Junior University Opsin polypeptides and methods of use thereof
CN104363961B (zh) 2012-02-21 2017-10-03 斯坦福大学托管董事会 用于治疗盆底神经源性病症的组合物和方法
CN103006642B (zh) * 2013-01-04 2014-10-22 中国药科大学 一类炔亚甲基吲哚-2-酮类衍生物的用途
JP6594854B2 (ja) 2013-03-15 2019-10-23 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 行動状態の光遺伝学的制御方法
US9636380B2 (en) 2013-03-15 2017-05-02 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic control of inputs to the ventral tegmental area
WO2014179331A2 (en) 2013-04-29 2014-11-06 The Board Of Trustees Of The Leland Stanford Junior University Devices, systems and methods for optogenetic modulation of action potentials in target cells
CN103242332B (zh) * 2013-05-13 2015-11-04 江西科技师范大学 1-n酰基取代吲哚酮衍生物
CN104530065A (zh) * 2013-05-13 2015-04-22 江西科技师范大学 1-n酰基取代吲哚酮衍生物的应用
JP6621747B2 (ja) 2013-08-14 2019-12-18 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 疼痛を制御するための組成物及び方法
CN103420941B (zh) * 2013-08-26 2015-09-23 浙江大学 2-甲氧基苯基-二甲胺基甲酸酯衍生物及制备和用途
US10568516B2 (en) 2015-06-22 2020-02-25 The Board Of Trustees Of The Leland Stanford Junior University Methods and devices for imaging and/or optogenetic control of light-responsive neurons
US11294165B2 (en) 2017-03-30 2022-04-05 The Board Of Trustees Of The Leland Stanford Junior University Modular, electro-optical device for increasing the imaging field of view using time-sequential capture

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3573310A (en) * 1967-09-28 1971-03-30 Miles Lab 1-substituted derivatives of 2-indolinone
US3635976A (en) * 1967-12-20 1972-01-18 Pennwalt Corp 1 - heterocyclic alkyl-1 2 3 4-tetrahydroquinazolinones and analgesic intermediates thereof
DE2123923A1 (de) * 1971-05-14 1972-11-23 Boehringer Mannheim Gmbh, 6800 Mannheim 4-eckige Klammer auf omega- (Flavon-7yl-oxy) -alkyl eckige Klammer zu -pigerazin-Derivate und Verfahren zu ihrer Herstellung
GR65270B (en) * 1978-10-10 1980-07-31 Fujisawa Pharmaceutical Co Isatin derivatives and processes for the preparation thereof
US4692448A (en) * 1984-11-20 1987-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Bis(arylpiperazinyl)sulfur compounds
JPS62294654A (ja) * 1986-06-13 1987-12-22 Kissei Pharmaceut Co Ltd イサチン誘導体
FI95572C (sv) * 1987-06-22 1996-02-26 Eisai Co Ltd Förfarande för framställning av ett som läkemedel användbart piperidinderivat eller dess farmaceutiska salt
FR2651230B1 (fr) * 1989-08-25 1992-03-13 Synthese Rech Derives de la 5-amino-1,2,3,4 tetrahydro-acridine et applications comme medicaments.
RU2124511C1 (ru) * 1993-05-14 1999-01-10 Фармасьютикал Ко., Лтд Производные пиперазина
SE9302080D0 (sv) * 1993-06-16 1993-06-16 Ab Astra New compounds

Also Published As

Publication number Publication date
BG98815A (bg) 1995-05-31
SK278321B6 (en) 1996-10-02
CN1034939C (zh) 1997-05-21
JPH07502272A (ja) 1995-03-09
MX9207382A (es) 1993-07-01
AU3175993A (en) 1993-07-19
FI942913A (sv) 1994-08-17
EP0624156A1 (en) 1994-11-17
AP9200464A0 (en) 1993-01-31
HUT69704A (en) 1995-09-28
ZA929700B (en) 1993-08-10
SI9200405A (en) 1993-06-30
NO942316D0 (no) 1994-06-17
SK73494A3 (en) 1995-03-08
TNSN92114A1 (fr) 1993-06-08
AU675055B2 (en) 1997-01-23
AP389A (en) 1995-08-02
CA2124826A1 (en) 1993-06-24
EE9400428A (et) 1996-04-15
NO942316L (no) 1994-06-17
IL104107A0 (en) 1993-05-13
HU9401844D0 (en) 1994-09-28
IS3958A (is) 1993-06-19
CN1079464A (zh) 1993-12-15
PL170736B1 (pl) 1997-01-31
CZ146694A3 (en) 1995-06-14
US5585378A (en) 1996-12-17
WO1993012085A1 (en) 1993-06-24
FI942913A0 (sv) 1994-06-17

Similar Documents

Publication Publication Date Title
SE9103752D0 (sv) New compounds
BR9806752A (pt) Ftalazinonas.
DK0840732T3 (da) Substituerede benzolactamforbindelser som substans P-antagonister
ES2080297T3 (es) Derivados 17-g(b)-sustituido-4-aza-5g(a)-androstan-3-ona y procedimiento de preparacion de estos.
DK0646115T3 (da) Heterocykliske/cykliske aminderivater
DE69823344D1 (de) Substituierte benzimidazol-derivaten und ihre verwendung zur behandlung retroviraler infektionen
NO20011721L (no) N-aralkylaminotetraliner som ligander for neuropeptid Y Y5- reseptoren
TR200003206T2 (tr) İndol türevleri ve patolojik hücre çoğalmasının neden olduğu habis hastalıklar ve diğer hastalıkların tedavisinde kullanımları.
DE60026155D1 (de) Einige alkylendiamin-substituierte heterocyclen
BR0209149A (pt) Ftalazinonas
BR0215360A (pt) Derivados de indolina úteis como inibidores de proteìna quinase
FI873631A0 (fi) --alkyl-4-amino-3-kinolinmetanoler och 1-(4-aralkylamino-3-kinolinyl)alkanoler, foerfarande foer deras framstaellning och deras anvaendning som laekemedel.
DK0907639T3 (da) Polymorfe forbindelser
TR200001690T2 (tr) Triazin damar gelişimi önleyicileri
DE60012751D1 (de) Verwendung von ep4 rezeptorliganden zur behandlung von neuropathischen schmerz
DE69819525D1 (de) Acridine derivate zur verbesserung der oralen bioverfügbarkeit von taxol
ATE324890T1 (de) Zusammensetzung enthaltend einen angiotensin-ii- rezeptor-antagonist und einen diuretikum und deren verwendung zur behandlung von bluthochdruck
DE69823493D1 (de) Tetrahydropyridoverbindungen
TR199902094T2 (xx) 3-Heteroareil-4(3H)-kinazolinonlar�n atropizomerleri.
ATE342261T1 (de) Pyranderivate als inhibitoren von ace und nep
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
ATE235450T1 (de) 2-indanmethanolderivate und ihre verwendung als riechstoffe
TR200103169T2 (tr) 1,5-Benzodiazepin türevleri
DE69528288D1 (de) Indolderivate zur behandlung von migräne